Loading…
Shree Ganesh Remedies (SGRL)₹608.65−3.26%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Shree Ganesh Remedies reported sales of ₹14.40 Cr, down 41.8% from Jun 2025, and net profit of ₹1.13 Cr, down 67.3% year on year. For the year to Mar 2026, sales were ₹109 Cr and net profit ₹18.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.47 | 24.88 | 32.44 | 27.15 | 24.51 | 24.75 | 30.41 | 21.17 | 33.29 | 14.40 |
| Expenses | 20.43 | 16.69 | 21.07 | 17.18 | 14.60 | 17.41 | 20.74 | 14.42 | 21.87 | 11.04 |
| Operating Profit | 16.88 | 8.10 | 11.27 | 9.87 | 9.84 | 7.27 | 9.58 | 6.70 | 11.34 | 3.34 |
| OPM % | 45.4% | 32.8% | 35.0% | 36.7% | 40.5% | 29.6% | 31.7% | 31.9% | 34.3% | 23.3% |
| Other Income | 1.33 | 0.55 | 0.20 | 0.72 | 2.30 | 0.67 | 0.70 | 0.67 | 1.03 | 0.95 |
| Interest | 0.14 | 0.33 | 0.45 | 0.40 | 0.98 | 0.95 | 1.02 | 0.75 | 0.89 | 0.33 |
| Depreciation | 1.85 | 2.01 | 2.41 | 2.69 | 2.41 | 2.41 | 2.58 | 2.66 | 2.79 | 2.43 |
| Profit before tax | 16.23 | 6.32 | 8.63 | 7.52 | 8.77 | 4.59 | 6.70 | 3.97 | 8.71 | 1.52 |
| Tax % | 22.4% | 26.7% | 25.8% | 27.9% | 24.8% | 25.0% | 26.2% | 22.3% | 28.2% | 27.4% |
| Net Profit | 12.61 | 4.66 | 6.43 | 5.44 | 6.61 | 3.46 | 4.97 | 3.10 | 6.29 | 1.13 |
| EPS (Rs) | 9.87 | 3.64 | 5.01 | 4.24 | 5.15 | 2.70 | 3.87 | 2.42 | 4.90 | 0.88 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 35.15 | 64.27 | 49.16 | 126 | 109 | 109 | 99.27 |
| Expenses | 26.09 | 52.15 | 35.10 | 84.18 | 69.24 | 74.17 | 68.07 |
| Operating Profit | 8.96 | 12.94 | 13.94 | 41.84 | 38.84 | 34.86 | 30.96 |
| OPM % | 25.0% | 20.0% | 28.0% | 33.0% | 36.0% | 32.0% | 31.2% |
| Other Income | 1.01 | 4.01 | 2.01 | 3.01 | 4.01 | 3.01 | 3.35 |
| Interest | 0.00 | 0.99 | 0.00 | 0.99 | 2.01 | 4.01 | 2.99 |
| Depreciation | 0.99 | 1.99 | 2.99 | 5.99 | 9.98 | 9.99 | 10.46 |
| Profit before tax | 8.99 | 13.97 | 12.98 | 37.95 | 30.96 | 23.98 | 20.90 |
| Tax % | 28.0% | 23.0% | 24.9% | 25.9% | 26.0% | 26.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.12 | 0.63 | 1.21 | — |
| Net Profit | 6.01 | 10.02 | 10.02 | 28.04 | 23.07 | 18.05 | 15.49 |
| EPS (Rs) | 4.90 | 8.21 | 7.65 | 22.04 | 18.03 | 13.89 | 12.07 |
| Dividend payout % | 17.9% | 13.0% | 17.9% | 2.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9.01 | 9.02 | 13.02 | 13.03 | 13.03 |
| Reserves | 25.05 | 33.07 | 109 | 132 | 150 |
| Borrowings | 1.01 | 4.01 | 36.08 | 38.11 | 31.07 |
| Other Liabilities | 7.00 | 9.00 | 12.01 | 8.04 | 13.95 |
| Total Liabilities | 41.07 | 55.10 | 171 | 192 | 208 |
| Fixed Assets | 14.05 | 20.06 | 81.32 | 95.37 | 105 |
| CWIP | 0.00 | 0.00 | 16.98 | 8.99 | 12.99 |
| Investments | 3.99 | 2.99 | 4.99 | 17.96 | 12.97 |
| Other Assets | 23.03 | 32.05 | 69.11 | 70.04 | 78.08 |
| Inventories | 6.53 | 6.43 | 25.05 | 22.09 | 24.07 |
| Trade receivables | 9.71 | 17.78 | 20.32 | 22.25 | 32.54 |
| Cash & equivalents | 0.99 | 2.32 | 16.21 | 10.01 | 13.45 |
| Total Assets | 41.07 | 55.10 | 171 | 192 | 208 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −4.99 | 4.99 | 2.99 | 29.99 | 30.97 | 23.99 |
| Cash from investing activity | 0.00 | −3.01 | −1.01 | −33.12 | −35.09 | −9.03 |
| Cash from financing activity | 0.00 | 0.00 | −1.01 | 10.01 | −1.01 | −12.02 |
| Net cash flow | −5.01 | 1.01 | 2.01 | 7.01 | −6.01 | 3.01 |
| Capex | 0.09 | 0.03 | 0.02 | 31.16 | 23.18 | 16.59 |
| Free cash flow | −4.99 | 5.01 | 3.01 | −0.99 | 6.99 | 7.01 |
| CFO / OP % | −60.0% | 37.0% | 24.0% | 92.0% | 104.0% | 82.0% |
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 101 | 101 | 59 | 75 | 109 |
| Inventory days | 125 | 61 | 156 | 223 | 209 |
| Days payable | 75 | 43 | 51 | 61 | 82 |
| Cash conversion cycle | 151 | 119 | 164 | 238 | 236 |
| Working capital days | 145 | 103 | 89 | 111 | 128 |
| ROCE % | — | 35.0% | — | 19.0% | 14.0% |
For the Jun 2026 quarter, Shree Ganesh Remedies reported sales of ₹14.40 Cr, down 41.8% year on year and net profit of ₹1.13 Cr, down 67.3% year on year. The operating margin was 23.3%.
Shree Ganesh Remedies' sales for the year to Mar 2026 were ₹109 Cr; over the last twelve months they were ₹99.27 Cr.
Net profit for the year to Mar 2026 was ₹18.05 Cr, and ₹15.49 Cr over the last twelve months. Earnings per share over the same trailing period were ₹12.07.
Shree Ganesh Remedies reported borrowings of ₹31.07 Cr at Mar 2026, against cash and equivalents of ₹13.45 Cr.
Cash from operations was ₹23.99 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹7.01 Cr.